CH EPL (R5)
0.1.0 - ci-build

CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions

Example RegulatedAuthorization: Reimbursement SL 21208

Generated Narrative: RegulatedAuthorization FOPH-21208

CH - EPL Reimbursement SL

  • FOPHDossierNumber: urn:oid:2.16.756.1/21208
  • status: Reimbursed
  • statusDate: 2021-08-01
  • listingStatus: Listed
  • listingPeriod: 2021-08-01 --> (ongoing)
  • firstListingDate: 2021-08-01
  • costShare: 10
  • gamme: Oral

CH - EPL Product Price

  • value: CHF3,022.10 (CHF)
  • type: Ex-factory price
  • changeType: Price mutation after triennal review of pharmaceuticals
  • changeDate: 2024-01-01

CH - EPL Product Price

  • value: CHF3,347.10 (CHF)
  • type: Retail price
  • changeType: VAT-change
  • changeDate: 2024-01-01

subject: PackagedProductDefinition: identifier = http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-PCID#CH-7640109110007-6771901-001; containedItemQuantity = 72 Tablet; description = CUPRIOR Filmtabl 150 mg 72 Stk

type: Reimbursement SL

Indications

-ExtensionReference
*ClinicalUseDefinition: type = indication

holder: Organization Curatis AG

Generated Narrative: Organization #holder-Curatis-AG

identifier: urn:oid:1.2.276.0.76/100082791, GLN/7640109110007

name: Curatis AG